- Home
- RGA vs BBIO Comparison
RGA vs BBIO Comparison
Compare RGA & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RGA | BBIO |
|---|---|---|
| Founded | 1973 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Life Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.3B | 15.9B |
| IPO Year | 1996 | 2019 |
Fundamental Metrics
Financial Performance| Metric | RGA | BBIO |
|---|---|---|
| Price | $256.09 | $65.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 22 |
| Target Price | ★ $277.56 | $109.05 |
| AVG Volume (30 Days) | 309.7K | ★ 2.8M |
| Earning Date | 11-05-2026 | 10-28-2026 |
| Dividend Yield | ★ 1.53% | N/A |
| EPS Growth | ★ 64.86 | N/A |
| EPS | ★ 11.99 | N/A |
| Revenue | ★ $23,698,000,000.00 | $502,076,000.00 |
| Revenue This Year | $13.98 | $104.49 |
| Revenue Next Year | $4.59 | $65.30 |
| P/E Ratio | $21.35 | ★ N/A |
| Revenue Growth | 7.20 | ★ 126.26 |
| 52 Week Low | $178.21 | $52.75 |
| 52 Week High | $258.53 | $93.42 |
Technical Indicators
Market Signals| Indicator | RGA | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 65.47 | 33.30 |
| Support Level | $241.85 | $63.22 |
| Resistance Level | N/A | $70.37 |
| Average True Range (ATR) | 5.27 | 2.29 |
| MACD | 0.58 | 0.30 |
| Stochastic Oscillator | 97.96 | 21.83 |
Price Performance
Historical ComparisonAbout RGA Reinsurance Group of America Incorporated
Reinsurance Group of America Inc is an insurance holding company with operations in the United States, Latin America, Canada, Europe, Africa, Asia, and Australia. The core products and services include life reinsurance, living benefits reinsurance, group reinsurance, health reinsurance, financial solutions, facultative underwriting, and product development. The company's operations are divided into traditional and financial solution businesses.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.